SILVER SPRING, Md., Jan. 18, 2011 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today announced that the U.S. District Court for the Southern District of Texas entered a consent decree of permanent injunction against Deltex Pharmaceuticals Inc., of Rosenberg, Texas, its president, Kabir Ahmed, and vice president, Mohidur R. Khan.
The consent decree permanently prohibits/stops the company, Ahmed, and Khan from manufacturing and distributing drug products until Deltex's manufacturing operations and products are in compliance with federal law and the terms of the consent decree.
Deltex is a contract manufacturer and distributor of prescription and over-the-counter (OTC) drug products. The government's complaint, filed by the U.S. Department of Justice, detailed violations of the Federal Food, Drug, and Cosmetic Act involving manufacturing and distributing unapproved, adulterated, and misbranded drugs. Specifically, Deltex failed to obtain required FDA approval for its prescription drug products, failed to comply with FDA regulations governing OTC drug products, and failed to comply with current good manufacturing practice (cGMP) requirements.
"This injunction shows that FDA will seek enforcement action against companies that are identified as being in violation of our manufacturing and drug approval requirements," said Dara A Corrigan, FDA's associate commissioner for regulatory affairs.
The FDA provided ample prior notice to Deltex, a company with a history of significant violations of cGMP requirements, to cease marketing unapproved, adulterated, and misbranded drugs. FDA inspections of Deltex repeatedly found evidence that the defendants manufacture and distribute unapproved, adulterated, and misbranded drugs.
The FDA issued a Warning Letter to Deltex for manufacturing unap
|SOURCE U.S. Food and Drug Administration|
Copyright©2010 PR Newswire.
All rights reserved